Patients with systemic AL amyloidosis are not cured with conventional immunosuppressant treatment. However, early mortality rates have decreased and survival has improved as there has been a shift toward earlier diagnosis and therapy aimed at achieving remissions. The most commonly used regimen for AL amyloidosis is CyBorD, which consists of cyclophosphamide, bortezomib, and dexamethasone.
Primary amyloidosis medical therapy
Secondary amyloidosis medical therapy
Familial amyloidosis medical therapy
POEMS syndrome medical therapy
Renal amyloidosis medical therapy
Multiple myeloma medical therapy
Monoclonal gammopathy of undetermined significance secondary prevention
Cardiac amyloidosis medical therapy